Physician profile
John D Obrien
NPI 1497740203
$220.73
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.07 · 2021: $28.19 · 2022: $148.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $29.77 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.46 | 2022 | |
| Corium, LLC | $23.52 | 2022 | |
| Organon LLC | $21.20 | 2022 | |
| Abbvie INC. | $20.11 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.71 | 2022 | |
| Adlon Therapeutics L.P. | $14.42 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.01 | 2022 | |
| Novo Nordisk INC | $13.77 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $13.52 | 2022 | |
| Kaleo, INC. | $12.94 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.